Last reviewed · How we verify
NCT06371521
Ergogenic Effects of Sportlegs
Phase 1 trial testing Sportlegs in Performance Enhancing Product Use in 19 participants. Completed in 1 June 2024.
1 June 2024
Quick facts
| Lead sponsor | Christopher Bell |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | basic science |
| Enrollment | 19 |
| Start date | 24 January 2024 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Sportlegs
- Placebo
Conditions studied
- Performance Enhancing Product Use — all drugs for Performance Enhancing Product Use →
Sponsor
Christopher Bell — full company profile →
Who can join
Adults 18 to 30, any sex, with Performance Enhancing Product Use. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sportlegs is a commercially available dietary/sports supplement. It is manufactured by a local, Colorado-based company: Sport Specifics Inc. Although Sportlegs has been on the market for approximately 20-years, very little empirical research has been completed to determine if Sportlegs improves exercise performance. Sport Specifics Inc. has commissioned Colorado State University to investigate the ergogenic effects of Sportlegs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Influence of Acute Oral Lactate Supplementation on Responses to Cycle Ergometer Exercise: A Randomized, Crossover Pilot Clinical Trial.
Ewell TR, Bomar MC, Brown DM, Brown RL, et al · · 2024 · cited 5× · PMID 39203761 · DOI 10.3390/nu16162624
Verify or expand the search:
- PubMed search for NCT06371521
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Performance Enhancing Product Use
Currently open trials in the same condition.
- NCT07412951 — Effects of Caffeine and Shot Put Performance · NA · active not recruiting
- NCT06639789 — Effect of a New Formulation of Vitamin B12 on Physical and Mental · NA · recruiting
- NCT04273776 — A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, · EARLY_PHASE1 · active not recruiting
Other Christopher Bell trials
Trials by the same sponsor.
- NCT06011265 — Does Mirabegron Increase the Body Heat Generated by the Nervous System · EARLY_PHASE1 · completed
- NCT05285449 — Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota · NA · completed
- NCT05282693 — Ergogenic Properties of Magnesium Supplementation · NA · completed
- NCT05192239 — Influence of Edible Marijuana on Endurance Exercise Performance · EARLY_PHASE1 · completed
- NCT03180489 — Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss? · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06371521 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Christopher Bell
- Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06371521.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing